Kolon, T
Still unlicensed in humans outside of research investor.lilly.com/news-releases/ TRIUMPH-1: #retatrutide topline data Phase 3, n=2,339, 80 wk, obesity without diabetes (efficacy estimand): 12 mg: -28.3% body weight (-31.9 kg) 9 mg: -25.9% | 4 mg: -19.0% | Placebo: -2.2% 30% weight loss: 45.3% vs 0.5% 104-wk extension (BMI 35, n=532), 12 mg MTD: -30.3% Cross-trial context (obesity, no diabetes): STEP-1 SEMA 2.4 mg, 68 wk: -14.9% SURMOUNT-1 TZP 15 mg, 72 wk: -20.9% TRIUMPH-1 RETA 12 mg, 80 wk: -28.3% But: Topline press release
All applications are limited to laboratory and preclinical research use
Statistical analysis All data were statistically analyzed using GraphPad Prism 8.3.0 software
It targets bacterial cell walls, weakening them and ultimately leading to the destruction of the bacterial cells
American Family Physician, 100 (2), 116117